ORIC Pharmaceuticals Inc (STU:4TZ)
€ 9.4 0.2 (2.17%) Market Cap: 670.50 Mil Enterprise Value: 407.74 Mil PE Ratio: 0 PB Ratio: 2.30 GF Score: 42/100

Oric Pharmaceuticals Inc at Citi Virtual Oncology Leadership Summit Transcript

Feb 22, 2023 / 04:00PM GMT
Release Date Price: €4.2 (-1.41%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

All right. Great. Welcome back, everyone. I think everyone knows me. I'm Yigal Nochomovitz, one of the biotech analysts at Citi. This is the second day of Citi's Virtual Oncology Leadership Summit. It's great to have the senior management of ORIC here, Jacob Chacko and Pratik Multani. Thank you both so much for joining. We really appreciate the time.

Questions & Answers

Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Maybe, Jacob, if you want to just kick it off with the high-level introduction to ORIC. What's the business strategy? What are you focused on? A little bit on the 3 clinical stage programs that you're running right now? And some of the -- just your thoughts conceptually on how you select targets and your approach to drug development?

Jacob M. Chacko
ORIC Pharmaceuticals, Inc. - President, CEO & Director

Sure thing, Yigal. There's a lot wrapped up in that. Thank you for having us today. We appreciate

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot